Updates are available Correction dated 2020-02-03
Click to view Correction: https://doi.org/10.1007/s00508-020-01613-0
-
Authors
Wakolbinger, Robert
Muschitz, Christian http://orcid.org/0000-0002-4105-5361
Wallwitz, Jacqueline
Bodlaj, Gerd
Feichtinger, Xaver
Schanda, Jakob E.
Resch, Heinrich
Baierl, Andreas
Pietschmann, Peter
-
Funding
Funding for this research was provided by:
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 6 September 2019
Accepted: 9 December 2019
First Online: 7 January 2020
Change Date: 3 February 2020
Change Type: Correction
Change Details: <b>Correction to:</b>
Change Details: <b>Wien Klin Wochenschr 2019</b>
Change Details:
Change Details: https://doi.org/10.1007/s00508-019-01595-8
Change Details: The original version of this article unfortunately contained a��mistake. The last sentence should read: Patients with ALD had significantly lower sclerostin levels, compared to controls. The authors apologize for the ���
Conflict of interest
: J. Wallwitz is an employee at The Antibody Lab GmbH. Support in the form of research material was provided but no additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. C. Muschitz received speaker fees from Amgen, Novartis, Servier, Eli Lilly, Nycomed Pharma/Takeda, Kwizda Pharma, Boehringer Ingelheim, Actavis and Daiichi Sankyo. He also received educational grants/research support from the Austrian Society for Bone and Mineral Research, Roche Austria, Eli Lilly Austria, Eli Lilly International and Amgen Austria. He has nothing to disclose concerning this manuscript. P. Pietschmann received research support and/or fees from Amgen GmbH, Biomedica GmbH, DePuySynthes, Eli Lilly GmbH, Fresenius Kabi Austria, Meda Pharma/Mylan GmbH, Shire Austria GmbH, TAmiRNA GmbH and UCB Pharma. He has nothing to disclose concerning this manuscript. H. Resch received speaker fees from Amgen, Novartis, Servier, Eli Lilly, Nycomed Pharma/Takeda. He also received educational grants/research support from the Austrian Society for Bone and Mineral Research, Roche Austria, Eli Lilly Austria, Eli Lilly International and Amgen Austria. He has nothing to disclose concerning this manuscript. R. Wakolbinger, G. Bodlaj, X. Feichtinger, J.E. Schanda and A. Baierl declare that they have no competing interests.
